瑞舒伐他汀治疗脑梗死合并颈动脉粥样硬化患者的疗效

目的探讨瑞舒伐他汀对脑梗死患者颈动脉粥样硬化斑块的干预效果。方法选取80例脑梗死合并颈动脉粥样硬化斑块患者,随机分为对照组（n=40）和观察组（n=40）。对照组患者接受脑梗死常规治疗,观察组患者在常规治疗的基础上,加服12个月的瑞舒伐他汀（20mg,1次/晚）治疗。观察两组治疗前及治疗后3个月、6个月、12个月时的颈动脉粥样硬化斑块评分、血脂和C反应蛋白（CRP）水平变化。结果观察组患者治疗3个月、6个月、12个月时患者血清中胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、CRP水平较治疗前均有明显下降,同时高密度脂蛋白胆固醇（HDL-C）水平有所提高,与治疗前比较有显著统计学差异（P〈0.05）。对照组患者颈动脉粥样硬化斑块积分呈增加趋势,观察组患者颈动脉粥样硬化斑块积分呈降低趋势,两组患者在治疗6个月、12个月积分比较有统计学差异（P〈0.05）。结论瑞舒伐他汀对脑梗死合并颈动脉粥样动脉硬化斑块患者可起到强化降脂,促进斑块体积缩小的作用。

Curative effect of rosuvastatin on cerebral infarction complicating carotid atherosclerosis

Objective To discuss the intervention effect of rosuvastatin on carotid atherosclerotic plaques in the patients with cerebral infarction. Methods The patients （ n =80 ） with cerebral infarction complicating carotid atherosclerosis were randomly divided into control group （ n =40 ） and observation group （ n =40 ） . The control group was given routine therapy for cerebral infarction and observation group, oral rosuvastatin （ 20 mg every night ） for 12 months besides of the routine therapy. The scores of carotid atherosclerotic plaques and level changes of blood fat and C-reactive protein （ CRP ） were observed in two groups before treatment, and after treatment for 3, 6 and 12 months. Results In observation group, the levels of total cholesterol （ TC ） , triglyceride （ TG ） , low-density lipoprotein-cholesterol （ LDL-C ） and CRP decreased significantly, and the level of highdensity lipoprotein-cholesterol （ HDL-C ） increased after treatment for 3, 6 and 12 months compared with those before treatment （ P 0.05 ） . The scores of atherosclerotic plaques were （ 3.89 ± 0.58 ） , （ 3.39 ± 0.42 ） and （ 3.21 ± 0.54 ） respectively in observation group after 3, 6 and 12 months, and （ 3.82 ± 0.67 ） , （ 3.88 ± 0.44 ） and （ 3.90 ± 0.36 ） respectively in control group. The scores showed an increasing trend in control group and showed a decreasing trend in observation group. The comparison between the scores after 6 months and those after 12 months had statistical difference （ P 0.05 ） in two groups. Conclusion Rosuvastatin has the improving effects on reducing lipid and dissolving plaques in the patients with cerebral infarction complicating carotid atherosclerosis.